[Oral vaccination against smallpox (on the return of smallpox vaccination)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to V N Podkuĭko.
Explore the source record for details and available documents.
Oral and dermal administrations of vaccinia virus into rabbits, guinea pigs, and monkeys demonstrated a milder (without homeostasis disturbance) course of the vaccinal process with oral immunization, intensive immunity forming in minimal sensitization of the body was compared with dermal one. The results of revaccination in adults with oral smallpox vaccine and primary immunization in Ethiopia showed that oral immunization with vaccinia virus was safe, effective and lowly reactogenic. The comparative study of the preparation in remote revaccination (5 or more years later) proved its advantage over dermal vaccine. It consists in ecological safety (vaccinia virus excretion into the environment during 1 and 11 days, respectively, by 10-fold concentration reduction), reactogenicity (5 and 33% of common reactions, respectively) in the same immunogenicity.
Explore the source record for details and available documents.
The authors studied the penetration of variolo-vaccine virus through the mucosa of the small intestine of Macacus rhesus in enteral immunization, by immunofluorescent and virological methods. Fifteen minutes after the immunization the variolo-vaccine virus was revealed at the surface of the mucosal prismatic epithelium and in the t. mucosa propria within the cytoplasm of cells of the macrophage type. Dissemination of the process with detection of the variolo-vaccine virus in the blood, the lymph nodes, spleen and liver was determined within the range of 1 to 3 hours.
Residual virulence of three vaccinia strains: Neurovaccine, L-IVP, and its recombinant Revacs-B expressing HBs and preS2 antigens of hepatitis B virus is compared. Insertion of HBs and preS2 antigens of hepatitis B virus in the genome of vaccinia virus strain L-IVP decreases its residual virulence and leads to a benign course of vaccinal reaction involving no deaths of rabbits, cotton rats, or guinea pigs. We may expect that recombinant vaccine Revacs B based on L-IVP strain will cause no postvaccinal complications under conditions of an appreciable decrease in population immunity to vaccinia virus.
The results of fundamental and applied investigations on the development and trial of the oral administration of smallpox vaccine and live recombinant smallpox-hepatitis vaccine (Revax VT) in tablets are summarized. In comparative experiments on animals (rabbits, monkeys and guinea pigs) and human immunization the oral smallpox vaccine in tablets was shown to ensure equal effectiveness and greater safety in comparison with traditional smallpox vaccine for skin application. The study confirmed the natural and physiological character of oral immunization as a result of direct contact of immunogen with the mucous membrane of the digestive tract--an essential immunocompetent organ of the lymphoid system. The conclusion was made that oral immunization was the safe and most promising method of immunization against smallpox under modern conditions.
Results of comparative studies of tableted and epicutaneous live smallpox vaccines are presented. In experiments on rabbits by using histological, immunofluorescent, immunological and virological methods, higher safety and efficiency of the tableted vaccine than that of traditional smallpox epicutaneous vaccine were determined. The natural and physiological character of oral immunization was shown. The oral immunization was concluded to be a safe method of inoculation now and perspective for the use of recombinant vaccines based on vaccine virus in the absence of population immunity against smallpox.
High effectiveness of C.burnetii strain M-44 was confirmed in experimental studies on subcutaneously immunized guinea pigs ¿correction of pig] after their intratracheal infection with the virulent culture of the infective agent. The study revealed that the dose necessary for the enteral immunization of guinea pigs and monkeys was 10(4.8) -- 10(5.0) times less than that needed for the oral immunization of the animals. Live enteral vaccine obtained on the basis of this strain possessed sufficiently pronounced immunogenic and protective properties, protecting 75% of immunized monkeys from subcutaneous infection with C.burnetii virulent culture.
Explore the source record for details and available documents.
Presents the methods of oral and enteral administration of vaccines in tablets. Describes the method of oral administration with a sponge and the technique of administering large and small tablets in the intestinal tract. Describes the specific features of administering tablets to mice, guinea pigs, rabbits, and monkeys.